scholarly journals Intensive Glucose Control for Critically Ill Patients

2019 ◽  
Vol 26 (12) ◽  
pp. 1391-1392
Author(s):  
John Conway ◽  
Benjamin Friedman
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
Intensive Glucose Control

scholarly journals Is intensive glucose control bad for critically ill patients? A systematic review and meta-analysis

2020 ◽  
Vol 16 (9) ◽  
pp. 1658-1675 ◽  
Author(s):  
Ren-qi Yao ◽  
Chao Ren ◽  
Guo-sheng Wu ◽  
Yi-bing Zhu ◽  
Zhao-fan Xia ◽  
...  
Keyword(s):  
Systematic Review ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
Meta Analysis ◽  
Intensive Glucose Control

scholarly journals Intensive glucose control for critically ill patients: an updated meta-analysis

2018 ◽  
Vol 7 (12) ◽  
pp. 1288-1298 ◽  
Author(s):  
Yongli Fu ◽  
Yaowu Sun ◽  
Jiankun Zhang ◽  
Yu Cheng
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Random Effect ◽  
Cochrane Library ◽  
Short Term ◽  
Intensive Glucose Control ◽  
Medical Icus

This meta-analysis aims to update the evidence for the effects of intensive glucose control (IGC) on the outcomes among critically ill patients. We performed a systematic literature review from inception through December, 2017 by two independent authors by searching PubMed, EMBASE and Cochrane Library. Randomized clinical trials of the effects of IGC compared with conventional glucose control were selected. Random-effect models were applied to calculate summary relative risks (RRs) for the related outcomes. Of 4247 records identified, we abstracted data from 27 relevant trials for meta-analysis. Compared with patients receiving conventional glucose control (controls), patients with IGC did not have significantly decreased risk of short-term mortality (in-hospital mortality or intensive care unit (ICU) mortality) (RR 0.99, 95% CI 0.92–1.06) or 3- to 6-month mortality (RR 1.02, 95% CI 0.97–1.08). These results remained constant among different study settings including surgical ICUs, medical ICUs or mixed ICUs. Similarly, we also found that patients with IGC did not have significantly lower risk of sepsis (RR 1.00, 95% CI 0.89–1.11) or new need for dialysis (RR 0.97, 95% CI 0.84–1.11). However, patients with IGC had almost 4-fold increase in risk of hypoglycemia (RR 4.86, 95% CI 3.16–7.46). In conclusion, in this updated meta-analysis of published trials, critically ill patients receiving IGC were found to be at neutral risk for short-term or 3- 6-month mortality, risk of sepsis or new need for dialysis, but at higher risk of hypoglycemia.

In Silico Evaluation of Glucose Control Protocols for Critically Ill Patients

2012 ◽  
Vol 59 (1) ◽  
pp. 54-57 ◽  
Author(s):  
Jung Chan Lee ◽  
Myeungseon Kim ◽  
Ka Ram Choi ◽  
Tae Jung Oh ◽  
Min Young Kim ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
In Silico ◽  
Control Protocols

1075-P: Acute and Chronic Glucose Control in Critically Ill Patients with Diabetes: Impact of Prior Insulin Treatment

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 1075-P
Author(s):  
JAMES S. KRINSLEY ◽  
PETER R. RULE ◽  
JEAN-CHARLES PREISER ◽  
GREG ROBERTS ◽  
SHEHROSE CHAUDRY ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
Insulin Treatment ◽  
Patients With Diabetes

scholarly journals Saline versus 5% dextrose in water as a drug diluent for critically ill patients: a retrospective cohort study

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Yukari Aoyagi ◽  
Takuo Yoshida ◽  
Shigehiko Uchino ◽  
Masanori Takinami ◽  
Shoichi Uezono
Keyword(s):  
Blood Glucose ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
Blood Glucose Control ◽  
Kidney Injury ◽  
Saline Group ◽  
Significant Difference ◽  
The Impact ◽  
Electrolyte Abnormalities

Abstract Background The choice of intravenous infusion products for critically ill patients has been studied extensively because it can affect prognosis. However, there has been little research on drug diluents in this context. The purpose of this study is to evaluate the impact of diluent choice (saline or 5% dextrose in water [D5W]) on electrolyte abnormalities, blood glucose control, incidence of acute kidney injury (AKI), and mortality. Methods This before-after, two-group comparative, retrospective study enrolled adult patients who stayed for more than 48 h in a general intensive care unit from July 2015 to December 2018. We changed the default diluent for intermittent drug sets in our electronic ordering system from D5W to saline at the end of 2016. Results We included 844 patients: 365 in the D5W period and 479 in the saline period. Drug diluents accounted for 21.4% of the total infusion volume. The incidences of hypernatremia and hyperchloremia were significantly greater in the saline group compared to the D5W group (hypernatremia 27.3% vs. 14.6%, p < 0.001; hyperchloremia 36.9 % vs. 20.4%, p < 0.001). Multivariate analyses confirmed the similar effects (hypernatremia adjusted odds ratio (OR), 2.43; 95% confidence interval (CI), 1.54–3.82; hyperchloremia adjusted OR, 2.09; 95% CI, 1.31–3.34). There was no significant difference in the incidences of hyperglycemia, AKI, and mortality between the two groups. Conclusions Changing the diluent default from D5W to saline had no effect on blood glucose control and increased the incidences of hypernatremia and hyperchloremia.

472: ENTERIC LOCATION OF FEEDING AND ITS EFFECT ON BLOOD GLUCOSE CONTROL IN CRITICALLY ILL PATIENTS

2020 ◽  
Vol 48 (1) ◽  
pp. 217-217
Author(s):  
Brett Baney ◽  
Susan Lessar ◽  
Arthur Harralson ◽  
Jennifer Carter ◽  
Rachel Gaydos ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
Blood Glucose Control
Sign in / Sign up

Export Citation Format

Share Document